BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schwartz LH, Seymour L, Litière S, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, de Vries E. RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. Eur J Cancer 2016;62:138-45. [PMID: 27237360 DOI: 10.1016/j.ejca.2016.03.082] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 13.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu T, Zhou T, Luo F, Yang Y, Zhao S, Huang Y, Zhao H, Zhang L, Zhao Y. Clinical Significance of Kinetics of Low-Density Lipoprotein Cholesterol and Its Prognostic Value in Limited Stage Small Cell Lung Cancer Patients. Cancer Control 2021;28:10732748211028257. [PMID: 34184581 DOI: 10.1177/10732748211028257] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Meuten DJ, Moore FM, Donovan TA, Bertram CA, Klopfleisch R, Foster RA, Smedley RC, Dark MJ, Milovancev M, Stromberg P, Williams BH, Aubreville M, Avallone G, Bolfa P, Cullen J, Dennis MM, Goldschmidt M, Luong R, Miller AD, Miller MA, Munday JS, Roccabianca P, Salas EN, Schulman FY, Laufer-Amorim R, Asakawa MG, Craig L, Dervisis N, Esplin DG, George JW, Hauck M, Kagawa Y, Kiupel M, Linder K, Meichner K, Marconato L, Oblak ML, Santos RL, Simpson RM, Tvedten H, Whitley D. International Guidelines for Veterinary Tumor Pathology: A Call to Action. Vet Pathol 2021;:3009858211013712. [PMID: 34282984 DOI: 10.1177/03009858211013712] [Reference Citation Analysis]
3 Heinhuis KM, IJzerman NS, Koenen AM, van der Graaf WTA, Haas RL, Beijnen JH, Huitema ADR, van Houdt WJ, Steeghs N. PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study. BMJ Open 2020;10:e039449. [PMID: 32912994 DOI: 10.1136/bmjopen-2020-039449] [Reference Citation Analysis]
4 Rau KM, Liu CT, Hsiao YC, Hsiao KY, Wang TM, Hung WS, Su YL, Liu WC, Wang CH, Hsu HL, Chuang PH, Cheng JC, Tseng CP. Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response. J Clin Med. 2020;9. [PMID: 32071283 DOI: 10.3390/jcm9010188] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
5 Kumar R, Thiagarajan K, Jagannathan L, Liu L, Mayawala K, de Alwis D, Topp B. Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response. CPT Pharmacometrics Syst Pharmacol 2021;10:684-95. [PMID: 33938166 DOI: 10.1002/psp4.12637] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Bogani G, Vinti D, Murgia F, Chiappa V, Leone Roberti Maggiore U, Martinelli F, Ditto A, Raspagliesi F. Burden of lymphatic disease predicts efficacy of adjuvant radiation and chemotherapy in FIGO 2018 stage IIICp cervical cancer. Int J Gynecol Cancer 2019;29:1355-60. [DOI: 10.1136/ijgc-2019-000669] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
7 Eckardt JN, Wendt K, Bornhäuser M, Middeke JM. Reinforcement Learning for Precision Oncology. Cancers (Basel) 2021;13:4624. [PMID: 34572853 DOI: 10.3390/cancers13184624] [Reference Citation Analysis]
8 Grassberger C, Ngwa W. Modelling treatment-response rates. Nat Biomed Eng 2021;5:295-6. [PMID: 33864036 DOI: 10.1038/s41551-021-00717-w] [Reference Citation Analysis]
9 deSouza NM, Achten E, Alberich-Bayarri A, Bamberg F, Boellaard R, Clément O, Fournier L, Gallagher F, Golay X, Heussel CP, Jackson EF, Manniesing R, Mayerhofer ME, Neri E, O'Connor J, Oguz KK, Persson A, Smits M, van Beek EJR, Zech CJ; European Society of Radiology. Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR). Insights Imaging 2019;10:87. [PMID: 31468205 DOI: 10.1186/s13244-019-0764-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
10 Roviello G, Gambale E, Giorgione R, Santini D, Stellato M, Fornarini G, Rebuzzi SE, Basso U, Bimbatti D, Doni L, Nesi G, Bersanelli M, Buti S, De Giorgi U, Galli L, Sbrana A, Conca R, Carella C, Naglieri E, Pignata S, Procopio G, Antonuzzo L. Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study. Cancer Med 2022. [PMID: 35312175 DOI: 10.1002/cam4.4681] [Reference Citation Analysis]
11 Qu C, Zeng P, Wang H, Yuan C, Yuan H, Xiu D. Application of Magnetic Resonance Imaging in Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma. Magnetic Resonance Imaging. [DOI: 10.1002/jmri.28096] [Reference Citation Analysis]
12 Challapalli A, Pearson S, Mitra AV, Coe M, Thomson A, Elliott T, Kirkbride P, Pickering L, Kirk H, Foulstone E, Evans H, Bravo A, Bahl AK. A phase II trial of cabazitaxel as second line chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis. J Int Med Res 2019;47:4664-72. [PMID: 31502503 DOI: 10.1177/0300060519863546] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Kim IH, Shin SJ, Kang BW, Kang J, Kim D, Kim M, Kim JY, Kim CK, Kim HJ, Maeng CH, Park K, Park I, Bae WK, Sohn BS, Lee MY, Lee JL, Lee J, Lim ST, Lim JH, Chang H, Jung JY, Choi YJ, Kim YS, Cho J, Joung JY, Park SH, Lee HJ. 2020 Korean guidelines for the management of metastatic prostate cancer. Korean J Intern Med 2021;36:491-514. [PMID: 33561334 DOI: 10.3904/kjim.2020.213] [Reference Citation Analysis]
14 Lin J, Yang X, Long J, Zhao S, Mao J, Wang D, Bai Y, Bian J, Zhang L, Yang X, Wang A, Xie F, Shi W, Yang H, Pan J, Hu K, Guan M, Zhao L, Huo L, Mao Y, Sang X, Wang K, Zhao H. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr 2020;9:414-24. [PMID: 32832493 DOI: 10.21037/hbsn-20-338] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
15 Tsakatikas S, Papageorgiou G, Fioretzaki R, Kosmas C. An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors. Crit Rev Oncol Hematol 2021;166:103457. [PMID: 34428555 DOI: 10.1016/j.critrevonc.2021.103457] [Reference Citation Analysis]
16 Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, Newbold K, Smit J. 2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. Eur Thyroid J. 2019;8:227-245. [PMID: 31768334 DOI: 10.1159/000502229] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 17.3] [Reference Citation Analysis]
17 Alessandrino F, Smith DA, Spierling A, Kikano E, Somarouthu B, Tirumani SH, Ramaiya NH. Cancer Clinical Trials: What Every Radiologist Wants to Know but Is Afraid to Ask. AJR Am J Roentgenol 2021;216:1099-111. [PMID: 33594911 DOI: 10.2214/AJR.20.22852] [Reference Citation Analysis]
18 Emile G, Penager S, Levy C, Johnson A, Allouache D, Lequesne J, Hrab I, Segura C, Morel A, Gunzer K, Faveyrial A, Cherifi F, Da Silva A. Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib. Oncol Lett 2022;23:25. [PMID: 34868362 DOI: 10.3892/ol.2021.13143] [Reference Citation Analysis]
19 Persigehl T, Poeppel TD, Sedlaczek O. [Radiological response assessment of modern immunotherapy using iRECIST]. Radiologe 2017;57:826-33. [PMID: 28812098 DOI: 10.1007/s00117-017-0289-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
20 Pasqualini C, Rubino J, Brard C, Cassard L, André N, Rondof W, Scoazec JY, Marchais A, Nebchi S, Boselli L, Grivel J, Aerts I, Thebaud E, Paoletti X, Minard-Colin V, Vassal G, Geoerger B. Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. Eur J Cancer 2021;150:53-62. [PMID: 33892407 DOI: 10.1016/j.ejca.2021.03.032] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Li Y, Guo W, Li X, Zhang J, Sun M, Tang Z, Ran W, Yang K, Huang G, Li L. Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers. Int J Oral Sci 2021;13:38. [PMID: 34785635 DOI: 10.1038/s41368-021-00145-1] [Reference Citation Analysis]
22 Lalchandani UR, Sahai V, Hersberger K, Francis IR, Wasnik AP. A Radiologist's Guide to Response Evaluation Criteria in Solid Tumors. Current Problems in Diagnostic Radiology 2019;48:576-85. [DOI: 10.1067/j.cpradiol.2018.07.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
23 Litière S, Collette S, de Vries EGE, Seymour L, Bogaerts J. RECIST — learning from the past to build the future. Nat Rev Clin Oncol 2017;14:187-92. [DOI: 10.1038/nrclinonc.2016.195] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
24 Farris MK, Wheless WH, Hughes RT, Soike MH, Masters AH, Helis CA, Chan MD, Cramer CK, Ruiz J, Lycan T, Petty WJ, Ahmed T, Leyrer CM, Blackstock AW. Limited-Stage Small Cell Lung Cancer: Is Prophylactic Cranial Irradiation Necessary? Pract Radiat Oncol. 2019;9:e599-e607. [PMID: 31271904 DOI: 10.1016/j.prro.2019.06.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
25 Riva G, Salonia L, Fassone E, Sapino S, Piano F, Pecorari G. Quality of Life in Electrochemotherapy for Cutaneous and Mucosal Head and Neck Tumors. J Clin Med 2021;10:4366. [PMID: 34640382 DOI: 10.3390/jcm10194366] [Reference Citation Analysis]
26 DE Santiago BG, López-Gómez M, Delgado-López PD, Gordo AJ, Neria F, Thuissard-Vasallo IJ, Gómez-Raposo C, Tevar FZ, Moreno-Rubio J, Hernández AM, Iglesias I, Casado E. RAS Mutational Status in Advanced Colorectal Adenocarcinoma Treated With Anti-angiogenics: Preliminary Experience With Liquid Biopsy. In Vivo 2021;35:2841-4. [PMID: 34410976 DOI: 10.21873/invivo.12571] [Reference Citation Analysis]
27 Massard C, Borget I, Farace F, Aspeslagh S, Le Deley M, Le Tourneau C, Bidard F, Pierga J, Dieras V, Hofman P, Spano J, Ferte C, Lacroix L, Soria J. RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. European Journal of Cancer 2017;83:185-93. [DOI: 10.1016/j.ejca.2017.05.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
28 Paderi A, Gambale E, Botteri C, Giorgione R, Lavacchi D, Brugia M, Mazzoni F, Giommoni E, Bormioli S, Amedei A, Pillozzi S, Matucci Cerinic M, Antonuzzo L. Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis. Molecules 2021;26:5789. [PMID: 34641331 DOI: 10.3390/molecules26195789] [Reference Citation Analysis]
29 Cao T, Lu Y, Wang Q, Qin H, Li H, Guo H, Ge M, Glass SE, Singh B, Zhang W, Dong J, Du F, Qian A, Tian Y, Wang X, Li C, Wu K, Fan D, Nie Y, Coffey RJ, Zhao X. A CGA/EGFR/GATA2 positive feedback circuit confers chemoresistance in gastric cancer. J Clin Invest 2022;132:e154074. [PMID: 35289315 DOI: 10.1172/JCI154074] [Reference Citation Analysis]
30 Hajjo R, Sabbah DA, Bardaweel SK, Tropsha A. Identification of Tumor-Specific MRI Biomarkers Using Machine Learning (ML). Diagnostics (Basel) 2021;11:742. [PMID: 33919342 DOI: 10.3390/diagnostics11050742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Zou J, Li C, Han Y, Xing Y, Zhan Y, Zuo C, Ren X, Xing R, Zhang N, Yuan Q. Efficacy of Camrelizumab in Advanced Non-Small-Cell Lung Cancer and Prognostic Analysis of Different PET/CT Features. Journal of Oncology 2022;2022:1-7. [DOI: 10.1155/2022/9942918] [Reference Citation Analysis]
32 Rui M, Zhang X, Huang J, Wei D, Li Z, Shao Z, Ju H, Ren G. The baseline oral microbiota predicts the response of locally advanced oral squamous cell carcinoma patients to induction chemotherapy: A prospective longitudinal study. Radiother Oncol 2021;164:83-91. [PMID: 34571091 DOI: 10.1016/j.radonc.2021.09.013] [Reference Citation Analysis]
33 Iwamoto H, Shimose S, Noda Y, Shirono T, Niizeki T, Nakano M, Okamura S, Kamachi N, Suzuki H, Sakai M, Kajiwara A, Itano S, Tanaka M, Yamaguchi T, Kuromatsu R, Koga H, Torimura T, On Behalf Of The Kurume Liver Cancer Study Group Of Japan. Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers (Basel) 2021;13:2786. [PMID: 34205099 DOI: 10.3390/cancers13112786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Katzenstein HM, Aguado A, Cheek B, Gresh R. Neonatal Liver Tumors. Clin Perinatol 2021;48:83-99. [PMID: 33583509 DOI: 10.1016/j.clp.2020.11.005] [Reference Citation Analysis]
35 Tunariu N, Blackledge M, Messiou C, Petralia G, Padhani A, Curcean S, Curcean A, Koh DM. What's New for Clinical Whole-body MRI (WB-MRI) in the 21st Century. Br J Radiol 2020;93:20200562. [PMID: 32822545 DOI: 10.1259/bjr.20200562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
36 Trägårdh E, Borrelli P, Kaboteh R, Gillberg T, Ulén J, Enqvist O, Edenbrandt L. RECOMIA-a cloud-based platform for artificial intelligence research in nuclear medicine and radiology. EJNMMI Phys 2020;7:51. [PMID: 32754893 DOI: 10.1186/s40658-020-00316-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
37 Colombo C, Giancola N, Fugazzola L. Personalized treatment for differentiated thyroid cancer: current data and new perspectives. Minerva Endocrinol (Torino) 2021;46:62-89. [PMID: 33213119 DOI: 10.23736/S2724-6507.20.03342-8] [Reference Citation Analysis]
38 Fendler A, Bauer D, Busch J, Jung K, Wulf-Goldenberg A, Kunz S, Song K, Myszczyszyn A, Elezkurtaj S, Erguen B, Jung S, Chen W, Birchmeier W. Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients. Nat Commun 2020;11:929. [PMID: 32066735 DOI: 10.1038/s41467-020-14700-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 8.5] [Reference Citation Analysis]
39 Watanabe K, Okuma Y, Kawai S, Nagamata M, Hosomi Y. Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma. Thorac Cancer 2021;12:1668-72. [PMID: 33830645 DOI: 10.1111/1759-7714.13892] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Perri F, Longo F, Fusco R, D'Alessio V, Aversa C, Pavone E, Pontone M, Marciano ML, Villano S, Franco P, Togo G, Fazio GR, Ordano D, Maglitto F, Salzano G, Maglione MG, Guida A, Ionna F. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers (Basel) 2021;13:2210. [PMID: 34064511 DOI: 10.3390/cancers13092210] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Hufnagl C, Leisch M, Weiss L, Melchardt T, Moik M, Asslaber D, Roland G, Steininger P, Meissnitzer T, Neureiter D, Greil R, Egle A. Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer. Oncol Lett 2020;19:1551-8. [PMID: 31966080 DOI: 10.3892/ol.2019.11192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
42 van Dam MA, Vuijk FA, Stibbe JA, Houvast RD, Luelmo SAC, Crobach S, Shahbazi Feshtali S, de Geus-Oei LF, Bonsing BA, Sier CFM, Kuppen PJK, Swijnenburg RJ, Windhorst AD, Burggraaf J, Vahrmeijer AL, Mieog JSD. Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. Cancers (Basel) 2021;13:6088. [PMID: 34885196 DOI: 10.3390/cancers13236088] [Reference Citation Analysis]
43 Dercle L, Ammari S, Bateson M, Durand PB, Haspinger E, Massard C, Jaudet C, Varga A, Deutsch E, Soria JC, Ferté C. Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence. Sci Rep 2017;7:7952. [PMID: 28801575 DOI: 10.1038/s41598-017-08310-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
44 Sun XS, Liang YJ, Chen QY, Guo SS, Liu LT, Sun R, Luo DH, Tang LQ, Mai HQ. Optimizing the Treatment Pattern for De Novo Metastatic Nasopharyngeal Carcinoma Patients: A Large-Scale Retrospective Cohort Study. Front Oncol 2020;10:543646. [PMID: 33194602 DOI: 10.3389/fonc.2020.543646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Xu X, Li R, Zhu P, Zhang P, Chen J, Lin Y, Chen Y. Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study. World J Surg Oncol 2021;19:231. [PMID: 34362384 DOI: 10.1186/s12957-021-02340-0] [Reference Citation Analysis]
46 Goebel J, Hoischen J, Gramsch C, Schemuth HP, Hoffmann AC, Umutlu L, Nassenstein K. Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria. J Cancer Res Clin Oncol 2017;143:2527-33. [PMID: 28825135 DOI: 10.1007/s00432-017-2488-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
47 Costa LB, Queiroz MA, Barbosa FG, Nunes RF, Zaniboni EC, Ruiz MM, Jardim D, Gomes Marin JF, Cerri GG, Buchpiguel CA. Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism. Radiographics 2021;41:120-43. [PMID: 33275541 DOI: 10.1148/rg.2021200093] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
48 Zhou X, Liu M, Ren Q, Zhu W, Wang Y, Chen H, Chen J. Oral and injectable Marsdenia tenacissima extract (MTE) as adjuvant therapy to chemotherapy for gastric cancer: a systematic review. BMC Complement Altern Med 2019;19:366. [PMID: 31830977 DOI: 10.1186/s12906-019-2779-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
49 Wu D, Li X, Zhang X, Han F, Lu X, Liu L, Zhang J, Dong M, Yang H, Li H. Pharmacometabolomics Identifies 3-Hydroxyadipic Acid, d-Galactose, Lysophosphatidylcholine (P-16:0), and Tetradecenoyl-l-Carnitine as Potential Predictive Indicators of Gemcitabine Efficacy in Pancreatic Cancer Patients. Front Oncol 2019;9:1524. [PMID: 32064236 DOI: 10.3389/fonc.2019.01524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Lowery MA, Yu KH, Kelsen DP, Harding JJ, Bomalaski JS, Glassman DC, Covington CM, Brenner R, Hollywood E, Barba A, Johnston A, Liu KC, Feng X, Capanu M, Abou-Alfa GK, O'Reilly EM. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. Cancer 2017;123:4556-65. [PMID: 28832976 DOI: 10.1002/cncr.30897] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
51 Lin J, Yang X, Xie Y, Zhao H. Unleashing The Potential Of Multiple-Targeted Therapies In Hepatobiliary Cancers: Two Cases, Cocktail Therapy With Nine Molecular Targeted Agents And Long-Lasting Survival. Onco Targets Ther 2019;12:9941-5. [PMID: 31819490 DOI: 10.2147/OTT.S223568] [Reference Citation Analysis]
52 de Bree R, Wolf GT, de Keizer B, Nixon IJ, Hartl DM, Forastiere AA, Haigentz M Jr, Rinaldo A, Rodrigo JP, Saba NF, Suárez C, Vermorken JB, Ferlito A. Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond. Head Neck 2017;39:2329-49. [PMID: 28815841 DOI: 10.1002/hed.24883] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
53 Butala AA, Patel RR, Manjunath S, Latif NA, Haggerty AF, Jones JA, Taunk NK. Palliative Radiation Therapy for Metastatic, Persistent, or Recurrent Epithelial Ovarian Cancer: Efficacy in the Era of Modern Technology and Targeted Agents. Adv Radiat Oncol 2021;6:100624. [PMID: 33665491 DOI: 10.1016/j.adro.2020.11.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
54 Alipour R, Azad A, Hofman MS. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol 2019;11:1758835919876828. [PMID: 31565073 DOI: 10.1177/1758835919876828] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
55 Chen HF, Wang WX, Xu CW, Huang LC, Li XF, Lan G, Zhai ZQ, Zhu YC, Du KQ, Lei L, Fang MY. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib. Lung Cancer 2020;142:59-62. [PMID: 32114282 DOI: 10.1016/j.lungcan.2020.02.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
56 Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, Allison T, Arnaout O, Abbosh C, Dunn IF, Mak RH, Tamimi RM, Tempany CM, Swanton C, Hoffmann U, Schwartz LH, Gillies RJ, Huang RY, Aerts HJWL. Artificial intelligence in cancer imaging: Clinical challenges and applications. CA Cancer J Clin. 2019;69:127-157. [PMID: 30720861 DOI: 10.3322/caac.21552] [Cited by in Crossref: 132] [Cited by in F6Publishing: 185] [Article Influence: 44.0] [Reference Citation Analysis]
57 Liu CY, Huang CC, Tsai YF, Chao TC, Lien PJ, Lin YS, Feng CJ, Chen JL, Chen YJ, Chiu JH, Hsu CY, Tseng LM. VGH-TAYLOR: Comprehensive precision medicine study protocol on the heterogeneity of Taiwanese breast cancer patients. Future Oncol 2021. [PMID: 34665002 DOI: 10.2217/fon-2021-0131] [Reference Citation Analysis]
58 Heinhuis KM, IJzerman NS, van der Graaf WTA, Kerst JM, Schrage Y, Beijnen JH, Steeghs N, van Houdt WJ. Neoadjuvant Systemic Treatment of Primary Angiosarcoma. Cancers (Basel) 2020;12:E2251. [PMID: 32806524 DOI: 10.3390/cancers12082251] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
59 Liu G, Wang C, He Y, E M. Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours. BMC Pharmacol Toxicol 2019;20:61. [PMID: 31661009 DOI: 10.1186/s40360-019-0362-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
60 Alghandour R, Ebrahim MA, Elshal AM, Ghobrial F, Elzaafarany M, ELbaiomy MA. Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED). Urol Oncol 2021;39:831.e1-831.e10. [PMID: 34167872 DOI: 10.1016/j.urolonc.2021.05.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Tanabe S. Cancer recognition of artificial intelligence. Artif Intell Cancer 2021; 2(1): 1-6 [DOI: 10.35713/aic.v2.i1.1] [Reference Citation Analysis]
62 Mammatas LH, Zandvliet AS, Rovithi M, Honeywell RJ, Swart EL, Peters GJ, Menke-van der Houven van Oordt CW, Verheul HMW. Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study. Cancer Chemother Pharmacol 2020;85:931-40. [PMID: 32274565 DOI: 10.1007/s00280-020-04065-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
63 Adler C, Lubner MG, Menias CO, Lubner SJ, Dahiya N. What's in a node? The clinical and radiologic significance of Virchow's node. Abdom Radiol (NY) 2022. [PMID: 35316379 DOI: 10.1007/s00261-022-03487-4] [Reference Citation Analysis]
64 Castiglioni I, Gallivanone F, Soda P, Avanzo M, Stancanello J, Aiello M, Interlenghi M, Salvatore M. AI-based applications in hybrid imaging: how to build smart and truly multi-parametric decision models for radiomics. Eur J Nucl Med Mol Imaging 2019;46:2673-99. [PMID: 31292700 DOI: 10.1007/s00259-019-04414-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
65 Berland L, Kim L, Abousaway O, Mines A, Mishra S, Clark L, Hofman P, Rashidian M. Nanobodies for Medical Imaging: About Ready for Prime Time? Biomolecules 2021;11:637. [PMID: 33925941 DOI: 10.3390/biom11050637] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18:e143-52. [PMID: 28271869 DOI: 10.1016/S1470-2045(17)30074-8] [Cited by in Crossref: 807] [Cited by in F6Publishing: 445] [Article Influence: 161.4] [Reference Citation Analysis]
67 Woo M, Devane AM, Lowe SC, Lowther EL, Gimbel RW. Deep learning for semi-automated unidirectional measurement of lung tumor size in CT. Cancer Imaging 2021;21:43. [PMID: 34162439 DOI: 10.1186/s40644-021-00413-7] [Reference Citation Analysis]
68 Switlyk MD. Magnetic resonance imaging for assessing treatment response in bone marrow metastases. Acta Radiol 2021;62:483-99. [PMID: 31154803 DOI: 10.1177/0284185119851234] [Reference Citation Analysis]
69 Eichkorn T, Regnery S, Held T, Kronsteiner D, Hörner-Rieber J, El Shafie RA, Herfarth K, Debus J, König L. Effectiveness and Toxicity of Fractionated Proton Beam Radiotherapy for Cranial Nerve Schwannoma Unsuitable for Stereotactic Radiosurgery. Front Oncol 2021;11:772831. [PMID: 34869012 DOI: 10.3389/fonc.2021.772831] [Reference Citation Analysis]
70 Alongi F, Fiorentino A, Gregucci F, Corradini S, Giaj-Levra N, Romano L, Rigo M, Ricchetti F, Beltramello A, Lunardi G, Mazzola R, Ruggieri R. First experience and clinical results using a new non-coplanar mono-isocenter technique (HyperArc™) for Linac-based VMAT radiosurgery in brain metastases. J Cancer Res Clin Oncol 2019;145:193-200. [PMID: 30382369 DOI: 10.1007/s00432-018-2781-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
71 Dubreuil J, Cachin F, Berriolo-ridinger A, Skanjeti A. Critères d’interprétation en imagerie cancérologique solide : RECIST, PERCIST…. Médecine Nucléaire 2017;41:241-8. [DOI: 10.1016/j.mednuc.2017.02.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
72 Larghi A, Rimbaș M, Rizzatti G, Carbone C, Gasbarrini A, Costamagna G, Alfieri S, Tortora G. Endoscopic ultrasound-guided therapies for pancreatic solid tumors: An overview. Semin Oncol 2021:S0093-7754(21)00004-X. [PMID: 33608132 DOI: 10.1053/j.seminoncol.2021.01.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Wang H, Mao X. Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. Drug Des Devel Ther 2020;14:2423-33. [PMID: 32606609 DOI: 10.2147/DDDT.S253961] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
74 Nobel JM, van Geel K, Robben SGF. Structured reporting in radiology: a systematic review to explore its potential. Eur Radiol 2021. [PMID: 34652520 DOI: 10.1007/s00330-021-08327-5] [Reference Citation Analysis]
75 Morgan RL, Camidge DR. Reviewing RECIST in the Era of Prolonged and Targeted Therapy. J Thorac Oncol 2018;13:154-64. [PMID: 29113950 DOI: 10.1016/j.jtho.2017.10.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
76 Berry JL, Munier FL, Gallie BL, Polski A, Shah S, Shields CL, Gombos DS, Ruchalski K, Stathopoulos C, Shah R, Jubran R, Kim JW, Mruthyunjaya P, Marr BP, Wilson MW, Brennan RC, Chantada GL, Chintagumpala MM, Murphree AL. Response criteria for intraocular retinoblastoma: RB-RECIST. Pediatr Blood Cancer 2021;68:e28964. [PMID: 33624399 DOI: 10.1002/pbc.28964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Song D, Man X, Jin M, Li Q, Wang H, Du Y. A Decision-Making Supporting Prediction Method for Breast Cancer Neoadjuvant Chemotherapy. Front Oncol 2020;10:592556. [PMID: 33469514 DOI: 10.3389/fonc.2020.592556] [Reference Citation Analysis]
78 Eichkorn T, Bozorgmehr F, Regnery S, Dinges LA, Kudak A, Bougatf N, Weber D, Christopoulos P, Muley T, Kobinger S, König L, Hörner-Rieber J, Adeberg S, Heussel CP, Thomas M, Debus J, El Shafie RA. Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer-Cross-Sectional Study of Eligibility and Administration Rates. Front Oncol 2020;10:586449. [PMID: 33335856 DOI: 10.3389/fonc.2020.586449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Duran-Moreno J, Kampoli K, Kapetanakis EI, Mademli M, Koufopoulos N, Foukas PG, Kostopanagiotou K, Tomos P, Koumarianou A. Pericardial Synovial Sarcoma: Case Report, Literature Review and Pooled Analysis. In Vivo 2019;33:1531-8. [PMID: 31471401 DOI: 10.21873/invivo.11633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
80 Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, der Kwast THV, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, der Poel HGV, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Mottet N. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol 2021;79:263-82. [PMID: 33039206 DOI: 10.1016/j.eururo.2020.09.046] [Cited by in Crossref: 54] [Cited by in F6Publishing: 65] [Article Influence: 27.0] [Reference Citation Analysis]
81 Tian Z, Gu Z, Wang X, Liu Z, Yao W, Wang J, Zhang P, Cai Q, Ge H. Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study. Medicine (Baltimore) 2019;98:e15650. [PMID: 31083265 DOI: 10.1097/MD.0000000000015650] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
82 Zambrana F, Carril-Ajuria L, Gómez de Liaño A, Martinez Chanza N, Manneh R, Castellano D, de Velasco G. Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news. Cancer Treat Rev 2021;99:102239. [PMID: 34157582 DOI: 10.1016/j.ctrv.2021.102239] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
83 Lewis H, Ghasabeh M, Khoshpouri P, Kamel I, Pawlik T. Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies. Surgical Oncology 2017;26:411-22. [DOI: 10.1016/j.suronc.2017.08.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
84 Ando Y, Kawaoka T, Kosaka M, Shirane Y, Johira Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Kosaka Y, Uchikawa S, Kodama K, Fujino H, Nakahara T, Ono A, Murakami E, Yamauchi M, Okamoto W, Takahashi S, Imamura M, Chayama K, Aikata H. Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice. Cancers (Basel) 2021;13:3958. [PMID: 34439111 DOI: 10.3390/cancers13163958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
85 Hess LM, Brnabic A, Mason O, Lee P, Barker S. Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology. J Cancer 2019;10:3717-27. [PMID: 31333789 DOI: 10.7150/jca.32205] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
86 Mohammed N, Zhou RR, Xiong Z. Imaging evaluation of lung cancer treated with PD-1/PD-L1 inhibitors. Br J Radiol 2021;94:20210228. [PMID: 34541867 DOI: 10.1259/bjr.20210228] [Reference Citation Analysis]
87 Omballi M, Fernandez-Bussy S, Patel PP, Jantz MA, Becnel D, Patel NM, Mehta HJ. Surveillance Imaging After Curative Intent Therapy for Lung Cancer. Semin Roentgenol 2020;55:60-9. [PMID: 31964482 DOI: 10.1053/j.ro.2019.10.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 Pinter M, Jain RK, Duda DG. The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. JAMA Oncol 2021;7:113-23. [PMID: 33090190 DOI: 10.1001/jamaoncol.2020.3381] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 34.0] [Reference Citation Analysis]
89 Golan T, Milella M, Ackerstein A, Berger R. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017). J Exp Clin Cancer Res 2017;36:192. [PMID: 29282151 DOI: 10.1186/s13046-017-0668-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
90 Que Y, Wang J, Zhu J, Li N, Huang J, Lu S, Sun F, Zhang L, Zhen Z, Zhang L, Cai R, Guo H, Sun X, Zhang Y. Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer. Front Immunol 2021;12:647733. [PMID: 34295326 DOI: 10.3389/fimmu.2021.647733] [Reference Citation Analysis]
91 Zhao L, Liu L, Zhao H, Bao J, Dou Y, Yang Z, Lin Y, Sun Z, Meng L, Yan L, Liu A. Therapy response assessment of non-small cell lung cancer using dual-energy computed tomography iodine map. J Xray Sci Technol 2021. [PMID: 34719473 DOI: 10.3233/XST-210989] [Reference Citation Analysis]
92 Mazzei MA, Di Giacomo L, Bagnacci G, Nardone V, Gentili F, Lucii G, Tini P, Marrelli D, Morgagni P, Mura G, Baiocchi GL, Pittiani F, Volterrani L, Roviello F. Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer-a multicenter study of GIRCG (Italian Research Group for Gastric Cancer). Quant Imaging Med Surg 2021;11:2376-87. [PMID: 34079708 DOI: 10.21037/qims-20-683] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA. High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. Oncotarget 2017;8:104430-43. [PMID: 29262651 DOI: 10.18632/oncotarget.22303] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
94 Vaflard P, Paoletti X, Servois V, Tresca P, Pons-Tostivint E, Sablin MP, Ricci F, Loirat D, Hescot S, Torossian N, Bello Roufai D, Kamal M, Borcoman E, Le Tourneau C. Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy. Drugs R D 2021;21:399-406. [PMID: 34562258 DOI: 10.1007/s40268-021-00362-3] [Reference Citation Analysis]
95 Chuma M, Uojima H, Hattori N, Arase Y, Fukushima T, Hirose S, Kobayashi S, Ueno M, Tezuka S, Iwasaki S, Wada N, Kubota K, Tsuruya K, Shimma Y, Hiroki I, Takuya E, Tokoro C, Iwase S, Miura Y, Moriya S, Watanabe T, Hidaka H, Morimoto M, Numata K, Kusano C, Kagawa T, Maeda S. Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. Hepatol Res 2021. [PMID: 34761470 DOI: 10.1111/hepr.13732] [Reference Citation Analysis]
96 Gorospe L, Pacios-Blanco RE, Garrido-López P. The Importance of Imaging Studies in the Assessment of Response to Immunotherapy in Lung Cancer. Arch Bronconeumol (Engl Ed) 2020;56:380-9. [PMID: 31898993 DOI: 10.1016/j.arbres.2019.10.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]